A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
Completed · Phase 1
Conditions studied: Alzheimer Disease
In brief
The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of \[18F\]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.
Key facts
- Study ID
- NCT04394845
- Run by
- Genentech, Inc.
- People needed
- 6
- Starts
- 2020-08-11
- Expected to finish
- 2020-10-09
- Last updated by the study team
- 2021-11-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Invicro, a Konica Minolta company — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.